
Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone
Author(s) -
Satriyo Dwi Suryantoro,
Mochammad Thaha,
Pranawa,
Djoko Santoso,
Nunuk Mardiana,
Widodo Widodo,
Aditiawardana,
Artaria Tjempakasari,
Ardityo Rahmat Ardhany,
Dana Pramudya,
Decsa Medika Hertanto,
Evy Febriane,
Meryana,
María Ángela,
Ari Christy Muliono,
Handoko Tanuwidjaja,
Philia Setiawan,
David Sugiarto
Publication year - 2021
Publication title -
journal of infection in developing countries
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.322
H-Index - 49
eISSN - 2036-6590
pISSN - 1972-2680
DOI - 10.3855/jidc.14952
Subject(s) - hydroxychloroquine , medicine , lopinavir , ritonavir , lopinavir/ritonavir , dexamethasone , kidney transplantation , transplantation , intensive care medicine , covid-19 , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load , disease , infectious disease (medical specialty)
Severe COVID-19 infection management for a recipient of kidney transplant has debatable prognosis and treatment. We described the case of a COVID-19 infected 70 year old female, previously had renal transplantation in 2017. The patient took immunosuppressive agents as routine drugs for transplant recipient status and received lopinavir/ritonavir, hydroxychloroquine, and dexamethasone daily at the hospitalization. Specific question arises about renal transplant recipients being infected by COVID-19 – whether the infection will get worse compared to those without immunosuppresive agent. In this case, author decided to stop the immunosuppressive agent followed administration of combination lopinavir/ritonavir, hydroxychloroquine, and dexamethasone that gives a good clinical impact change to patient’s condition after once getting worsened and mechanically ventilated. Nevertheless, the assessment of risk and benefit in continuing immunosuppressive drugs is concurrently essential due to the prevention of transplant rejection.